Bridgeway Capital Management, LLC Adverum Biotechnologies, Inc. Transaction History

Bridgeway Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.68 - $1.59 $34,000 - $79,500	50,000 New	50,000 $79,000
Q3 2022 Nov 14, 2022	BUY	$0.96 - $9.68 $54,720 - $551,760	57,000 Added 23.55%	299,000 $284,000
Q1 2022 May 16, 2022	BUY	$1.23 - $1.95 $297,660 - $471,900	242,000 New	242,000 $317,000
Q2 2019 Aug 14, 2019	SELL	$5.1 - $11.89 $1.14 Million - $2.66 Million	-223,600 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$3.03 - $6.02 $104,232 - $207,087	34,400 Added 18.18%	223,600 $1.17 Million
Q1 2018 May 15, 2018	BUY	$3.65 - $7.95 $19,345 - $42,135	5,300 Added 2.88%	189,200 $1.1 Million
Q3 2017 Nov 14, 2017	BUY	$2.45 - $3.65 $450,555 - $671,235	183,900	183,900 $671,000

2.53M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $689M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.